Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ContraVir's James Sapirstein Interviewed On Future Of Combination Therapy In HBV

Executive Summary

At BioPharm America 2016, ContraVir CEO James Sapirstein explains how CMX157, a lipid formulation of tenofovir (Gilead's Viread for HIV and hepatitis B), could become a backbone agent for advances in combination therapy in hep B.

Advertisement

Related Content

ContraVir Hopes To Establish Backbone For Hepatitis B Combo Therapy
ContraVir Strikes Deal With Rival Early Stage Hep B Drug Developer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097427

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel